Defining the role of TORC1/2 in multiple myeloma

Patricia Maiso, Yi Liu, Brittany Morgan, Abdel Kareem Azab, Pingda Ren, Michel B. Martin, Yong Zhang, Yang Liu, Antonio Sacco, Hai Ngo, Feda Azab, Phong Quang, Scott J. Rodig, Charles P. Lin, Aldo M. Roccaro, Christian Rommel, Irene M. Ghobrial

Research output: Contribution to journalArticlepeer-review

64 Scopus citations

Abstract

Mammalian target of rapamycin (mTOR) is a downstream serine/threonine kinase of the PI3K/Akt pathway that integrates signals from the tumor microenvironment to regulate multiple cellular processes. Rapamycin and its analogs have not shown significant activity in multiple myeloma (MM), likely because of the lack of inhibition of TORC2. In the present study, we investigated the baseline activity of the PI3K/Akt/mTOR pathway TORC1/2 in MM cell lines with different genetic abnormalities. TORC1/2 knock-down led to significant inhibition of the proliferation of MM cells, even in the presence of BM stromal cells. We also tested INK128, a dual TORC1/2 inhibitor, as a new therapeutic agent against these MM cell lines. We showed that dual TORC1/2 inhibition is much more active than TORC1 inhibition alone (rapamycin), even in the presence of cytokines or stromal cells. In vitro and in vivo studies showed that p-4EBP1 and p-Akt inhibition could be predictive markers of TORC2 inhibition in MM cell lines. Dual TORC1/2 inhibition showed better inhibition of adhesion to BM microenvironmental cells and inhibition of homing in vivo. These studies form the basis for further clinical testing of TORC1/2 inhibitors in MM.

Original languageEnglish
Pages (from-to)6860-6870
Number of pages11
JournalBlood
Volume118
Issue number26
DOIs
StatePublished - Dec 22 2011

Fingerprint

Dive into the research topics of 'Defining the role of TORC1/2 in multiple myeloma'. Together they form a unique fingerprint.

Cite this